Citalopram Safety Warning Has Serious Consequences for VA Patients
The Carlat Psychiatry Report, Volume 14, Number 7&8, July 2016
https://www.thecarlatreport.com/newsletter-issue/tcprv14n7and8/
Issue Links: Learning Objectives | Editorial Information
Topics: Depression | Research Update
Bret A. Moore, PsyD, ABPP
Board-Certified Clinical Psychologist, San Antonio, TX
Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In the summer of 2011, the Food and Drug Administration (FDA) reported that post-marketing surveillance showed that patients taking greater than 40 mg/day of citalopram were at greater risk of QT prolongation. Shortly thereafter, the Department of Veterans Affairs (VA) alerted its providers to this warning. VA researchers recently published a study detailing the results of this warning on patients.
You can't view details of this content, please login or buy subscription here